LEIDEN, The Netherlands--(BUSINESS WIRE)--Azafaros B.V. announced positive clinical data from its first-in-human Phase 1 study with AZ-3102, the company’s lead program in development as a potential ...
LEIDEN, The Netherlands--(BUSINESS WIRE)--Azafaros B.V. announced today that the first cohort of healthy subjects has been dosed in a two-part Phase 1 clinical study with clinical candidate AZ-3102, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results